Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs ABRDN Physical Gold Shares ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.09 (market cap $9.43B), while ABRDN Physical Gold Shares ETF trades at $41.9. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| BIO | SGOL | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $356.25 | $51.41 |
52-Week Low | $241.71 | $31.61 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
SGOL trades at $42.21, up 0.98% with a bullish technical signal from moving averages, though oscillators show caution with RSI at overbought levels. The gold ETF benefits from recent CPI data showing cooling inflation and strong central bank demand, with spot gold prices testing key resistance levels. Financial ratios remain unavailable for this commodity-focused ETF structure.
The outlook remains positive given gold's momentum and macroeconomic support, though overbought conditions suggest potential near-term consolidation. Key risks include Fed policy shifts and dollar strength, while institutional buying provides underlying support for the gold thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
